Synnovation Therapeutics synthesizes new NRF2 degraders
Summary
Synnovation Therapeutics has discovered new PROTAC compounds that target NRF2 for degradation. The compounds combine an E3 ubiquitin-protein ligase binding moiety with an NRF2-targeting moiety. The work points to potential cancer-treatment applications. This item focuses on scientific development rather than a commercial software event.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected